Doga Gulhan

Doga Gulhan, PhD

Assistant Professor of Medicine, Massachusetts General Hospital
Assistant Professor of Biomedical Informatics, Harvard Medical School (Secondary)

Doga Gulhan is the Principal Investigator of Gulhan Lab at Mass General Hospital (MGH) Cancer Center and a Faculty Member HMS. She received her Bachelor of Science degree from Bilkent University's Physics Department. She completed her Ph.D. in high-energy physics at the Massachusetts Institute of Technology and worked as a Research Fellow at CERN. After transitioning to biomedical informatics, she joined Park Lab at the Department of Biomedical Informatics at HMS as a postdoctoral fellow. She studied mutational processes in cancer using signature analysis techniques. She contributed new algorithms to this emerging field that expanded its clinical applications by enabling signature prediction from targeted gene panels (Gulhan et al Nat Genet. 2019) and robust signature discovery and assignments from whole exome and genome datasets (Jin, Gulhan et al Nat Genet. 2024). Her recent work focuses on understanding the immunogenomic and molecular characteristics of tumors with repair deficiencies. Her research program is dedicated to developing a comprehensive suite of tools for deciphering cancer genomes, aimed at personalized oncology. This includes the creation of statistical and machine-learning methods designed specifically for mutational signature analysis, clinical patient classification and tumor evolution inference.

Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency.
Authors: Kim YN, Gulhan DC, Jin H, Glodzik D, Park PJ.
Cancer Res Treat
View full abstract on Pubmed
Chromosome evolution screens recapitulate tissue-specific tumor aneuploidy patterns.
Authors: Watson EV, Lee JJ, Gulhan DC, Melloni GEM, Venev SV, Magesh RY, Frederick A, Chiba K, Wooten EC, Naxerova K, Dekker J, Park PJ, Elledge SJ.
Nat Genet
View full abstract on Pubmed
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Authors: Boiarsky D, Gulhan DC, Savignano H, Lakshminarayanan G, McClure HM, Silver R, Hirsch MS, Sholl LM, Choudhury AD, Ananda G, Park PJ, Tewari AK, Berchuck JE.
Clin Genitourin Cancer
View full abstract on Pubmed
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Authors: Konstantinopoulos PA, Cheng SC, Lee EK, da Costa AABA, Gulhan D, Wahner Hendrickson AE, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Penson RT, Stover EH, Curtis J, Sawyer H, Polak M, Chowdhury D, D'Andrea AD, Färkkilä A, Shapiro GI, Matulonis UA.
JCO Precis Oncol
View full abstract on Pubmed
Accurate and sensitive mutational signature analysis with MuSiCal.

Nat Genet
View full abstract on Pubmed
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures.

medRxiv
View full abstract on Pubmed
De novo identification of expressed cancer somatic mutations from single-cell RNA sequencing data.

Genome Med
View full abstract on Pubmed
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.

Clin Cancer Res
View full abstract on Pubmed
Author Correction: The landscape of somatic mutation in cerebral cortex of autistic and neurotypical individuals revealed by ultra-deep whole-genome sequencing.
Authors: Rodin RE, Dou Y, Kwon M, Sherman MA, D'Gama AM, Doan RN, Rento LM, Girskis KM, Bohrson CL, Kim SN, Nadig A, Luquette LJ, Gulhan DC, Park PJ, Walsh CA.
Nat Neurosci
View full abstract on Pubmed
ERa-associated translocations underlie oncogene amplifications in breast cancer.
Authors: Lee JJ, Jung YL, Cheong TC, Espejo Valle-Inclan J, Chu C, Gulhan DC, Ljungström V, Jin H, Viswanadham VV, Watson EV, Cortés-Ciriano I, Elledge SJ, Chiarle R, Pellman D, Park PJ.
Nature
View full abstract on Pubmed